Cargando…

FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression

Chemoresistance is common in patients with biliary tract cancer (BTC) including gallbladder cancer (GBC) and cholangiocarcinoma (CC). Therefore, it is necessary to identify effective chemotherapeutic agents for BTC. In the present study, we for the first time tested the effect of farnesoid X recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Zhan, Ming, Li, Qi, Chen, Wei, Chu, Huiling, Huang, Qihong, Hou, Zhaoyuan, Man, Mohan, Wang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085180/ https://www.ncbi.nlm.nih.gov/pubmed/27127878 http://dx.doi.org/10.18632/oncotarget.8964

Ejemplares similares

Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1
por: Li, Qiwei, et al.
Publicado: (2016)

Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
por: Yan, Meng, et al.
Publicado: (2022)

β-catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl
por: ZHANG, JIN, et al.
Publicado: (2016)

LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?
por: Cariello, Marica, et al.
Publicado: (2018)

Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver
por: Mathur, Bhoomika, et al.
Publicado: (2021)

Investigating the Role Intestinal-Specific FXR and SHP in Regulating Lipid Metabolism in Mice
por: Nguyen, James ThienToan, et al.
Publicado: (2021)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

OR22-01 Sex Differences In Enterohepatic Circulation Mediated By Hepatic FXR And SHP Depletions In Mice
por: Reichardt, Francois, et al.
Publicado: (2023)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma
por: Ho, I-Lin, et al.
Publicado: (2015)

Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax
por: Billen, Lieven P, et al.
Publicado: (2008)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer
por: Wei, Yumin, et al.
Publicado: (2023)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity
por: Park, Han-A, et al.
Publicado: (2017)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012)

miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer
por: Yang, Dong, et al.
Publicado: (2017)

Dynamics of Bcl-xL in Water and Membrane: Molecular Simulations
por: Maity, Atanu, et al.
Publicado: (2013)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Regulation of apoptosis by an intrinsically disordered region of Bcl-xL
por: Follis, Ariele Viacava, et al.
Publicado: (2018)

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2020)

The Role of Bcl-xL Protein Research in Veterinary Oncology
por: Pawlak, Aleksandra, et al.
Publicado: (2020)

Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition
por: Rahman, Masum, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uv2dh1qafvqqqsi4odoeqq1hbl